Home

Date register of trial

Trials for date register in the RPCEC

Date of Registration Public title Sponsor State
2009-05-29 rTMS-stroke-phase I CIREN Registered
2009-03-13 Clinical evaluation of the effect anti-inflammatory of the extract of Mangifera indica L. (Vimang®) in patients with diagnosis of Bronchial Asthma CQF Registered
2009-02-11 Phase II clinical trial for the evaluation of the therapeutic vaccine candidate Terap C. CIGB Registered
2009-02-11 Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis. CIGB Registered
2008-09-12 Challenge study to determine the protective efficacy of a single oral dose of the attenuated 638 strain. FINLAY Registered
2010-12-17 Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors. CIM Registered
2010-12-17 NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. CIM Registered
2010-12-17 99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II CIM Registered
2010-12-17 NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II CIM Registered
2009-02-11 Recombinant interferon alpha-2b in paranoid schizophrenia. CIGB Registered
2010-12-28 InCarbacel-II CIGB Registered
2008-10-16 FASECU I CIGB Registered
2008-09-18 Tisuacryl® in Dental Hyperesthesia BIOMAT Registered
2010-12-27 Hebervis administration in patients suffering from buccal mucositis caused by chemotherapy [unsealed CIGB Registered
2010-12-24 CIGB-128 administration to patients with surgically-treated keloids. CIGB Registered
2010-12-24 Application of CIGB-128 in keloid patients undergoing surgical exeresis. CIGB Registered
2009-02-26 CITOPROT-III CIGB Registered
2008-07-29 A phase II study of the Cuban adult formulation tetanus and diphtheria vaccine. FINLAY Registered
2008-07-29 A phase II study of the Cuban vaccine against tetanus and diphtheria VA-DIFTET. FINLAY Registered
2010-12-17 Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. CIM Registered